HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
265 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
(fiercepharma.com)
Asia—GSK's India Zantac plant sale; Takeda-BridGene drug discovery pact; Celltrion's COVID antibody
GlaxoSmithKline is selling its Zantac plant in India for a fraction of its original investment in the wake of a global recall. | GlaxoSmithKline sold a Zantac plant in India to Hetero Labs in the wake of a global recall. Takeda penned a drug discovery pact with BridGene focused on neurodegenerative disease. Celltrion's COVID-19 antibody won backing from EMA's drug reviewers ahead of an official nod. And more.
Read more